Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 11/20 | 0.42 |
| ▸ | F3 | P13726 | 11/20 | 0.42 |
| ▸ | F2 | P00734 | 6/20 | 0.42 |
| ▸ | F10 | P00742 | 6/20 | 0.42 |
| ▸ | F11 | P03951 | 6/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910772 | 1.00 | MEN1 (0.43) | MEN1KMT2ANR1H2F7F3 | |
| SCHEMBL2910770 | 1.00 | MEN1 (0.43) | MEN1KMT2ANR1H2F7F3 | |
| SCHEMBL2916946 | 0.87 | F7 (0.45) | F7F3F2F10F11 | |
| SCHEMBL13613598 | 0.86 | NR1H2 (0.43) | MEN1KMT2ANR1H2NPSR1LMNA | |
| SCHEMBL13613594 | 0.86 | NR1H2 (0.43) | MEN1KMT2ANR1H2NPSR1LMNA | |
| SCHEMBL13613597 | 0.86 | NR1H2 (0.43) | MEN1KMT2ANR1H2NPSR1LMNA | |
| SCHEMBL13613436 | 0.84 | MEN1 (0.46) | MEN1KMT2ANR1H2NPSR1LMNA | |
| SCHEMBL2912061 | 0.80 | NR1H2 (0.41) | MEN1KMT2ANR1H2F7F3 | |
| SCHEMBL3077286 | 0.80 | NR1H2 (0.41) | MEN1KMT2ANR1H2F7F3 | |
| SCHEMBL2913738 | 0.80 | NR1H2 (0.41) | MEN1KMT2ANR1H2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856096-B1 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | MEN1 2580/4885KMT2A 860/4885NR1H2 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.